Opening Ceremony

08:20-08:40

Group Photo(Place: Gate of ECEC)

09:00-09:05

Chair' s Opening Remark

09:05-09:35

VIP' s Address

Keynote Forum

09:40-10:05

Title: Bench, thru Human Diseases and onto Novel Drug Targeting
Dr. Aaron Ciechanover, Nobel Prize Laureate in Chemistry, 2004, Professor, Vascular and Cancer Biology Research Center, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Israel

10:05-10:30

Title: Roche R&D Center( China )Ltd.: A New Way of Drug Discovery
Dr. Andreas Claudius Tschirky, General Manager of Roche R&D Center China(RRDCC), China

10:30-10:55

Title: Milestone in Immunotherapies, New Targets and Biomarkers
Dr. Vincent G. Brichard, Vice President, Immunotherapeutics Business Unit, GlaxoSmithKline Biologicals S.A., Belgium

10:55-11:20

Title: Timely Chemical Process Research is a Critical Part for Efficient Drug Development
Dr. Chris Senanayake, Vice President, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., USA

11:20-11:45

Title: Seeking Competitive Edge in a Changing Landscape of Drug Innovation via Partnering
Dr. Jing-Shan Hu, Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan), Merck & Co., USA

18:30-20:30

Welcome Banquet and Art Performance

Chair:

Dr. Jun Li, Principal Scientist, Bristol-Myers Squibb, USA

Dr. Jun Li is a principal scientist at Bristol-Myers Squibb (BMS). Over the past twelve years at BMS, his team has discovered and delivered five development candidates in the areas of endocrine and metabolic diseases; two candidates are currently in human clinical trials. Dr. Li received his Ph. D. in organic chemistry from Iowa State University in 1994, and continued his post-doctoral research at Cornell University from 1996 to1997. Dr. Li was originally trained as an analytical chemist in China . He received his BS in 1985 from University of Science and Technology of China, and his MS in analytical chemistry from Chinese Academy of Science in 1988. He then moved to the Chinese Academy of Medical Sciences, initially as a research scientist and quickly became a group leader in the pharmaceutical analytical chemistry lab, where he served as one of the pioneers for China 's first accredited Doping Control Lab and development of doping control protocols/methods for China . His contribution was recognized as a recipient of China's prestigious R&D award: “First Prize, Advancement of Science & Technology Award, State Ministry of Science and Technology, China, 1992”, as well as other national awards. During his tenure with BMS, Dr. Li also received two “Molecule of the Year” awards. Over the years, he has co-authored or co-invented 40+ publications and patents, and has been an active speaker at conferences and symposiums.

Co-Chair:

Dr. Jiming Ye, Principal Investigator, Team Leader of Anti-Diabetic Therapeutics, Diabetes and Obesity Program, Garvan Institute of Medical Research, Australia

Dr Ye received his PhD (1995) and postdoc training in the University of Tasmania (Australia) involving studies on vascular regulation of fuel metabolism in obesity. He joined the Garvan Institute in 1997 and has since focused on the pathogenesis and reversal of insulin resistance. His initial work has revealed an important role of LCACoAs in the development of insulin resistance. Dr Ye’s subsequent translational research characterized the therapeutic profile of new drugs specific at PPAR,and in animal models using hyperinsulinaemic clamp (gold standard) combined with glucose tracers. Concurrently, his studies provided the “Proof of Concept” for the use of pharmacological AMPK activator in vivo to reverse insulin resistance. Furthermore, Dr Ye has adopted targeted approaches and new assays (eg. GLUT4 translocation) to screen synthetic and TCM derived compounds for the discovery of novel therapeutics. Dr Ye also has direct experience in phase 2-4 multicenter clinical trials for new drugs from his work in Eli Lilly (2003-2004).

08:10-08:30

Keynote Speech:
Title: Bombesin Receptor Subtype-3 Agonists as a Potential Treatment for Obesity
Dr. Xiao-Ming Guan, Senior Investigator, Merck Research Laboratories, USA

08:30-08:50

Title: Novel Approaches for the Discovery and Development of New Antidiabetic Drugs from Traditional Chinese Medicines
Dr. Jiming Ye, Team Leader of Antidiabetic Therapeutics, Diabetes and Obesity Research Program, The Garvan Institute of Medical Research, Australia

08:50-09:10

Title: Function Promoting Anabolic Therapy: Discovery of a Novel Tissue Selective Androgen Receptor Modulator
Dr. Bajin Han, Senior Investigator, Section Head, Muscle Metabolism DPU, GlaxoSmithKline, Inc., USA

09:10-09:30

Title: The Effect Colesevelam HCL On Glycemic Control In Insulin Resistant Rat Model
Dr. Guorong Xu, Professor, Department of Medicine, University of Medicine & Dentistry of New Jersey and VA Medical Center, USA

09:30-09:50

Title: New therapeutic Approaches to Type 2 Diabetes and Metabolic Syndrome
Dr. Guoqing Cao, Research Advisor, Lilly Research Laboratories, USA

09:50-10:10

Title: Transcriptional Suppression of PCSK9: A New Therapeutic Strategy to Treat Hypercholesterolemia
Dr. Jingwen Liu, Principal Investigator, VA Palo Alto Health Care System, USA

10:10-10:30

Coffee Break

10:30-10:50

Title: Balancing Cardiac Liabilities and PK Properties: Discovery of Triazolopyridine Based Growth Hormone Secretagogues
Dr. Jun Li, Principal Scientist, Discovery Chemistry, Bristol-Myers Squibb, USA

10:50-11:10

Title: Longitudinal Growth, New Pathways to Target?
Dr. Ragnar Bjarnason, Professor, University of Iceland, Iceland

11:10-11:30

Title: Gender Difference in Rat and Rabbit Aortic Endothelial Function under Acute Hyperglycemic Conditions; Involvement of Protein Kinase C β and Superoxide
Dr. Roshanak Rahimian, Associate Professor, University of the Pacific, USA

11:30-11:50

Title: Novel Players in Lipid Metabolism Revealed by Genome Wide Association Studies: Translation to Treatment of Dyslipidemia and Cardiovascular Disease
Dr. Marju Orho-Melander, Associate professor, Department of Clinical Sciences, Lund University, Sweden

11:50-12:10

Title: A Small Peptide And Pancreatic Beta Cell Function
Dr. LuGuang Luo, Associate Professor, Boston University and Brown University, School of Medicine, USA

12:10-12:30

Title: Effect of Chromium on GLUTs Expression in Diabetic Rat Brain
Dr. Kazim Sahin, Professor, Veterinary Faculty Firat University, Turkey

Chair:

Dr. Chaohong Sun, Group Leader, Fragment Based Lead Discovery Advance Technology, Abbott Laboratories, USA

Chaohong Sun received her BS from University of Science and Technology of China in 1993 and the same year, she went to USA to pursue her graduate work at Dartmouth College. After receiving her PhD in Biophysical Chemistry in 1998, she joined Dr. Stephen Fesik’s group at Abbott Laboratories as a post-doctoral fellow to study apoptosis pathway protein structures and functions using NMR in combination with other biophysical tools. Her work has resulted in a number of peer-reviewed publications. She was converted to staff scientist at Abbott in 2000. Over the years, she has dt steps of drug discovery proeveloped a number of new fragment based screening methods and expanded the applications of NMR to differencess. Currently, Dr. Sun is leading the Fragment Screening and Lead Characterization Group at Abbott and continues to explore and apply fragment based and structure based approaches for drug discovery.

Co-Chair:

Dr. Tatsuya Niimi, Senior Researcher, Chemistry Research Labs, Astellas Pharam Inc., Japan

Dr. Tatsuya Niimi obtained a doctorate in biochemisty from the University of Tokyo in 1995. He joined Riken as a special postdoctoral researcher and joined Yamanouchi Pharmaceutical Inc (now Astellas Pharmaceutical Inc) where he directed research computational chemistry as well as structural biology.

13:30-13:55

Title: Novel Antibiotic from Natural Products: Oxazolomycin, Reutericyclin and Equisetin.
Dr. Mark Moloney, Professor of Chemistry, Department of Chemistry, University of Oxford, Chemistry Research Laboratory, UK

13:55-14:20

Title: Drug Discovery Facilitated by Fragment Screening Efforts
Dr. Michael Hennig, Head of Discovery Technologies, F. Hoffmann - La Roche Ltd., Switzerland

14:20-14:45

Title: Development and NMR Validation of Minimal Pharmacophore Hypotheses for the Generation of Fragment Libraries Enriched in Heparanase Inhibitors
Dr. Antonio Pineda-Lucen, Principal Investigator, Structural Biology Laboratory, Medicinal Chemistry Department, Prince Felipe Research Center, Spain

14:45-15:10

Title: Electron transfer: The omitted booster when composing the herbal extract to therapeutics in pharmacy.
Dr. Pauli Virtanen, Laboratory Manager and Vice Director, Turku University, Finland

15:10-15:30

Coffee Break

15:30-15:55

Title: Evolving Trends and Opportunities for Fragment Based Screening
Dr. Chaohong Sun, Group Leader, Fragment Based Lead Discovery Advance Technology, Abbott Laboratories, USA

15:55-16:20

Title: Fragment-Based Drug Design in Astellas: Processes and Applications
Dr. Tatsuya Niimi, Senior Researcher, Chemistry Research Labs, Astellas Pharam Inc., Japan

16:20-16:45

Title: Intersection of Biophysical Studies and Drug Design. Use of the "Efficiency Coefficient" and "Drug Design Matrix
Dr. Michael J. Shapiro, Associate Professor, University of Maryland, USA

16:45-17:10

Panel Discussion
3-5 Topics will be Proposed by Session Chair

Chair:

Dr. Karin Moelling, Professor, Institute of Medical Virology, University of Zurich, Switzerland

Karin Moelling, female, is molecular biologist and virologist. She graduated in nuclear physics, studied molecular biology in Berkeley, Cal., USA. She was an independent research group leader at the Max Planck Institute of Molecular Genetics in Berlin. From 1993 to 2008 she was Director and Professor at the Institute of Medical Virology at the University of Zurich and is presently Fellow of the Institute of Advanced Studies at Berlin. She discoverd the viral RNase H, and identified the function of several oncogenes, such as the transcription factor Myc and the Raf kinase. She performed a Phase I cinical study with plasmid DNA coding for the cytokine IL-12, in melanoma patients. She developed antibodies against abeta protein involved in AD. Recently she developed a suicide mechanism of HIV activating the viral RNAse H. It inactivates cell-free virus particles in the blood taken from patients and vagina in mice and may be worth developing as microbicide. A mechanism called small interfering DNA, siDNA , consisiting of a hairpin-loop structured DNA, allowed inhibition of Influenza virus  replication in the lung of mice.HCV and HBV are onloing. Industrial partners are welcome

Co-Chair:

Dr. Marie-Paule Teulade-Fichou, Research director, CNRS, co-director of the laboratory of Chemistry, Institut Curie, France

Marie-Paule Teulade-Fichou is a Research Director at CNRS and currently the co-director of the laboratory of Chemistry of the Institut Curie, France. She was educated at University P. & M. Curie in Paris and took up a position at CNRS, in 1986, to developed research on new organophosphorus compounds at the Ecole Polytechnique in the group of Prof. F. Mathey (Palaiseau). In 1991 she joined the group of Prof. J.-M. Lehn at the College de France, where she developed macrocylic chemistry towards recognition of nucleic acids. Her current interest is focused on the design of new nucleic acids targeted drugs for anticancer research and for elucidating DNA-related molecular basis of cancer.

08:10-08:30

Keynote Speech:
Title: Executing the Pharmaceutical Potential of RNA Silencing
Dr. Bo Hansen, Director, Molecular Targets & Technology, Santaris Pharma, Danmark

08:30-08:50

Title: Silencing of Viral and Cancer RNAs by Small Double-Stranded siDNA
Dr. Karin Moelling, Professor, Institute of Medical Virology, University of Zurich, Switzerland

08:50-09:10

Title: Antibiotics Binding to the Dimerization Initiation Site of HIV-1 Genomic RNA
Dr. Philippe Dumas, Head of team 'Biophysics and Structural Biology', IBMC-CNRS, France

09:10-09:30

Title: New Prospects of Developing Triplex and G-quadruplex Drugs by Conjugation of Intercalators to DNA
Dr. Erik B. Pedersen, Professor, University of Southern Denmark, Denmark

09:30-09:50

Title: Targeting G-quadruplex DNA with Small Molecules: Implications for Anticancer Drug Discovery
Dr. Marie-Paule Teulade-Fichou, Research director, CNRS, Co-director of the laboratory of Chemistry, Institut Curie, France

09:50-10:10

Title: Regulating Viral Gene Expression with Aptamers
Dr. Jean-Jacques Toulmé, Director, Inserm U869, European Institute of Chemistry and Biology, University of Bordeaux, France

10:10-10:30

Coffee Break

Chair:

Mr. John H. Van Drie, President, John H Van Drie Research LLC, USA

In a career spanning more than 20 years in pharmaceutical discovery research, John H. Van Drie has distinguished himself both in the development of novel computational methods, and in their real-world application to drug discovery. Under methodology development, he is most well-known for his work on pharmacophore methods and virtual screening. He was (1) the author of ALADDIN, the first software to perform pharmacophore-based 3D database searching; (2) co-author of Catalyst, software still marketed by Accelrys; and (3) author of DANTE, for pharmacophore discovery. In applications to drug discovery, he was (1) a member of the team which discovered ritonavir, the first HIV protease inhibitor for AIDS, introduced in 1994; (2) he was the modeler on the team which discovered linezolid, the first antibiotic to specifically treat drug-resistant bacterial infections, introduced in 2001; and (3) he was a member of the team which discovered VX-950, an inhibitor of Hepatitis C virus protease, now in phase III trials.
He is currently President of Van Drie Research, a venture devoted to the development and application of novel computational approaches to drug discovery.   He has worked at Novartis, Vertex, Pharmacia & Upjohn, BioCAD, and was a consultant to Abbott. He was trained as a theoretical chemist at Caltech, and also studied as a BAEF Fellow at the Univ. Libre de Bruxelles.  He was Chair of the Gordon Conference on Computer-Aided Drug Design in 2003. 

Co-Chair:

Dr. Jian Wan, Professor, Central China Normal University, China

Upon completion of his doctorate in quantum chemisty at the University of Kyoto in 2000 he joined the Key Laboratory of Pesticide & Chemical Biology (CCNU), Ministry of Education at Central China Normal University. Research interest is employing and developing a variety of state-of-the-art computational approaches (semi-empirical MO methods, ab initio methods, density-functional theory, hybrid methods, molecular dynamics methods) to theoretically study on the molecular spectroscopic properties of various chemical and biological systems of interest, quantitative structure-activity relationships (QSARs), and structure-based inhibitor design. This led to the development of density functional theory (DFT) based 2D-QSARs (Wan et al. 2004) and molecular docking-based 3D-QSARs schemes (Wan et al. 2007) in structure-based inhibitor design and screening.

08:30-08:50

Keynote Speech:
Title: Advances in QSAR Studies on Calcium Channel Blockers
Dr. Satya P. Gupta, Professor of Eminence, Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, India

08:50-09:10

Title: The Role of CADD in Drug Design
Mr. John H. Van Drie, President, John H Van Drie Research LLC., USA

09:10-09:30

Title: Allosteric Inhibition of Human Peroxiredoxin
Dr. Art E. Cho, Professor, Korea University, Korea

09:30-09:50

Title: Structure-based Design of Aurora A & B Inhibitors
Dr. Anders Poulsen, Senior Scientist & Lab Head, S*BIO Pte Ltd., Singapore

09:50-10:10

Title: QSARs Modeling and its Application to Rational Inhibitor Design & Virtual Screening
Dr. Jian Wan, Professor, Central China Normal University, China

10:10-10:30

Coffee Break

10:30-10:50

Title: Molecular Simulation Approaches to Drug Design
Dr. Paolo Carloni, Professor, International School for Advanced Studies, Italy

10:50-11:10

Title: In Silico Models of Viral Channel Forming Proteins
Dr. Wolfgang B. Fischer, Associate Professor, Institute of Biophotonics, School of Biomedical Science and Engineering, National Yang-Ming University, Taiwan

11:10-11:30

Title: Molecular Modeling Studies of A3 Adenosine Receptor Modulators Using Machine Learning and Docking Methods
Dr. Sun Choi, Professor, College of Pharmacy and Division of Life & Pharmaceutical Sciences, National Core Research Center for Cell Signaling & Drug Discovery, Ewha Womans University, Korea

11:30-11:50

Title: Development of QSAR Models for Predicting Inhibition of Tubulin Polymerization in the Design of Anticancer Drugs
Dr. Ilaria Massarelli, Italian Interuniversitary Consortium of Materials Science and Technology, Italy

Chair:

Dr. John Spencer, professor in Medicinal Chemistry, University of Greenwich at Medway, UK

Dr Spencer is a graduate of Sussex University and did his PhD studies in palladium chemistry at the Université Louis Pasteur, Strasbourg (Dr Michel Pfeffer) before carrying out postdoctoral studies at the ETH, Zurich (Prof Antonio Togni). He has 10 years’ experience working as a medicinal chemist in small biotech and research organisations (e.g. James Black Foundation, 2001-2006). He has been a Reader at Greenwich since 2006 and his research interests include palladium catalysis (Chem. Rev. 2005, 2527, Tetrahedron 2008, 6082), microwave mediated synthesis (Tetrahedron, 2008, 10195) and general medicinal chemistry (Bioorg. Med. Chem. 2008, 2974). He is on the editorial advisory panel for “Future Medicinal Chemistry” and is a Fellow of the Royal Society of Chemistry.

13:30-13:55

Title: Microwave and Flow Cell Assisted Synthesis of Bioactive Molecules
Dr. John Spencer, professor in Medicinal Chemistry, University of Greenwich at Medway, UK

13:55-14:20

Title : A New Method of Serching for Ligand, Virtual Screening Based on Docking Study
Dr. Shigeo Fujita, Senior Director, Exploratory Research Div., Astellas Research Technolkogies Co., Ltd., Japan

14:20-14:45

Title: In Silico Search for Multi-target Anti-inflammatories in Chinese Herbs and Formulas
Dr. Dave Barlow, Reader, King's College London, UK

14:45-15:10

Title: Virtual High Throughput Screening in Anticancer Drug Discovery.
Dr. Jóhannes Reynisson, Lecturer, Department of Chemistry & Auckland Bioengineering Institute, The University of Auckland, New Zealand

15:10-15:30

Coffee Break

Chair:

Dr. Travis Stams, Director, Biomolecular Structure Novartis Institutes for Biomedical Research, USA

Travis is the Director of Biomolecular Structure at the Novartis Institutes for Biomedical Research (NIBR) in Cambridge, Massachusetts. He received his Ph.D. in Biological Chemistry from the University of Pennsylvania where his research focused on structure function relationships of metalloenzymes, including a focus on catalytic RNAs. Prior to obtaining his degree he worked for Eastman Kodak/Sterling Winthrop Pharmaceuticals as a member of the crystallography group, contributing to drug discovery efforts of metalloproteases. In 1998, Travis joined Novartis as a crystallographer with a primary focus on diabetes drug discovery. He became the head of the Biomolecular Structure Group in 2005, with responsibility for structural biology support of small molecule drug discovery in the areas of Oncology, Cardiovascular, Diabetes, and Infectious Disease research. In addition, Travis played a key role in establishing higher throughput biophysical characterization in hit finding and validation at NIBR, leading to his current role as head of the Biophysics Network at NIBR Cambridge. Currently, Travis also serves as the chairman of the Industrial Macromolecular Crystallography Association (IMCA) supervisory board, which operates two synchrotron beamlines at Argonne National Laboratory.

Co-Chair:

Dr. Hai-Liang Zhu, Professor, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China

After achieved his Ph.D degree in bioinorganic chemistry at Nanjing University in 1998 he finished 4 years’ postdoctoral work at Zhongshan University and Philipps-University Marburg. At the beginning of 2002, he founded his own research group at Wuhan University of Science & Engineering and at Nanjing University. His research interests include: (1) Design and Synthesis of Natural-Product-based New Drugs: Generating drug precursors for generation of new drugs based on natural products, (2) Metal-Based Drugs: Generating novel d-transition metal-based drug precursors of anti-gout and anti-Helicobacter pylori agents.

Chair:

Dr. Ronald J Quinn, Professor & Director, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Australia

Ronald Quinn obtained his PhD from the University of New South Wales (Australia) in 1970.  Following post-doctoral research in the USA, he joined the Roche Research Institute of Marine Pharmacology in Sydney (1974 – 1981). He joined Griffith University in 1982 and is Professor and Director of the Eskitis Institute for Cell and Molecular Therapies at GU. He is the author or co-author of over 170 publications and patents. Research interests concentrate on developing an understanding of molecular interactions involved in biological processes. This has included development of Nature Bank, a unique library of 200,000 natural product fractions derived from a collection of over 45,000 samples of plants and marine invertebrates collected from mega-diverse areas.

Co-Chair:

Dr. Ming-Qiang Zhang, Chief Technology Officer & Vice President of External Research, Roche R&D Centre (China) Ltd, Shanghai, China

Dr Zhang is currently Chief Technology Officer and Vice-President of External Research of Roche R&D China. Before joining Roche, he was Senior Vice-President of R&D at Biotica Technology Ltd (2004-2009), Cambridge, UK; Director of Medicinal Chemistry at Shire Pharmaceuticals Group PLC (2002-2004) and Section Head of Medicinal Chemistry at Organon (now Schering-Plough, 1997-2002). Prior to joining the industry, Dr Zhang held academic positions at the Leiden-Amsterdam Center for Drug Research (LACDR). Dr Zhang co-founded ViroChem Pharma Inc in Montreal, Canada, which was recently acquired by Vertex for US$380 millions. During his career, Dr Zhang has led the discovery of multiple candidate drugs progressed to clinical development or commercialization for potential treatment of CNS, cancer, inflammatory and infectious diseases. He is a (co-)author/inventor of over 100 scientific publications and patents. His discovery of Sugammadex (Bridion®) was awarded the 2007 Malcolm Campbell Memorial Prize in Biological and Medicinal Chemistry by the Royal Society of Chemistry.

Chair:

Dr.Ingo Ott, Professor, Institute of Pharmaceutical Chemistry, Technical University Braunschweig, Germany

Ingo Ott studied Pharmacy at the University of Innsbruck in Austria and obtained his “Approbation” (license to work as pharmacist) in 2000. He then moved on to the Institute of Pharmacy of Freie Universität Berlin, Germany, where he received his PhD in the group of Prof. R. Gust in 2004. From 2004 to 2008 he was faculty member at the same institute and performed postdoctoral research in the group of Prof. X. Qian at the Shanghai Key Laboratory of Chemical Biology at East China University of Science and Technology in Shanghai, China. In January 2009 he was appointed Assistant Professor of Pharmaceutical / Medicinal Chemistry at the Institute of Pharmaceutical Chemistry at Technische Universität Carolo-Wilhelmina zu Braunschweig, Germany. His major research interest is the development of novel anticancer drugs with the focus on bioinorganic and bioorganometallic compounds.

Co-Chair:

Dr. Chien-Tien Chen, Professor, Department of Chemistry, National Taiwan Normal University, Taiwan

Chien-Tien Chen received his his Ph.D. degree in chemistry in 1994 under the instruction of Prof. Scott E. Denmark at the Univ. of Illinois at Urbana-Champaign. He then moved to the Scripps Research Institute and pursued postdoctoral research from 1994-195 under the guidance of Professor K. Barry Sharpless. He returned to Taiwan in 1995 and became an associate professor at National Taiwan Normal University and was promoted to a full professor at the same university in 2000. He received the Science and Liberal-Art Foundation Distinguished Young Investigator Award from National Tsing-Hua University in 2000, the Outstanding Research Award from the National Science Council of Taiwan in 2006, and Academic Publication Award from The Sun Yat-Sen Cultural Foundation in 2007. He served as a member in the Advisory Board of the Organic Division of the Natural Science for the National Science Council of Taiwan since 2006. He was an ISIR-Osaka University Visiting Scholar from July 1 to August 31 in 2005 and received JSPS Organic Chemistry Asian Core Lectureship from July 15 to July 26 in 2007. He currently is a Research Chair of the National Taiwan Normal University. Starting January 1st of 2009, he serves as one of the chief officers at the chemistry division of the Natural Science at the National Science Council of Taiwan. His research interests cover asymmetric synthesis and catalysis, organic optoelectronic materials and LC-based optical switches, catalytic DNA photocleavages, and nanoparticle-encapsulated dendritic probes.

10:30-10:55

Title: Bioorganometallic and Bioinorganic Compounds as Anticancer Drugs
Dr. Ingo Ott, Professor, Institute of Pharmaceutical Chemistry, Technical University Braunschweig, Germany

10:55-11:20

Title: Development and Characterization of PH-switchable Metal ion-binding Receptor-pocket Models
Dr. Béla Noszál, Professor, Semmelweis University, Hungary

11:20-11:45

Title: Directed Evolution of C4-Symmetric Metal Vanadate-Centered Helical Quadruplexes: Synergistic Ion-specific Transport and Asymmetric Catalysis
Dr. Chien-Tien Chen, Professor, Department of Chemistry, National Taiwan Normal University, Taiwan

11:45-12:10

Title: Transition Metal Catalysis for Natural Product Modification
Dr. Man Kin Wong, Assistant Professor; Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China

Chair:

Dr. Jianling Wang, Head, ADME Profiling Cambridge, Novartis Institutes for Biomedical, USA

Dr. Wang is a senior scientist at the Novartis Institute for Biomedical Research in Cambridge, MA. He received a BS from Jilin University and an MS from the Chinese Academy of Sciences in chemistry. In 1992, he obtained his PhD in biophysical chemistry from the University of New Mexico. He then extended his career as a postdoctoral fellow at AT&T Bell Laboratories. In 1995, he joined Novartis (formerly Ciba-Geigy) and was dedicated to the discovery of isoform-selective inhibitors of iNOS and COX-2 and in the analyses of the combi-chem and in vivo PK/PD studies using confocal microscopy. Since 1998, Dr Wang’s research has been devoted to the establishment of novel techniques in high-throughput ADME profiling to improve drug discovery and development strategies. He has successfully established the physico-chemical profiling program in the US and developed a fully automated solubility assay using a nephelometric approach. Recently he has taken additional responsibilities by leading the early ADME program in Novartis. He is responsible for the development and implementation of a number of fully automated ADME assays such as high-throughput equilibrium solubility, artificial and Caco-2 permeability, pKa, LogP/D, chemical and metabolic stability, CYP-450 inhibition, metabolite ID, protein-binding and rate of dissolution, in support of the drug discovery research throughout the company.

Co-Chair:

Dr. Sheila Annie Peters, Associate Principal Scientist, Discovery DMPK & Bioanalytical Chemistry, AstraZeneca R&D, Sweden

Sheila Annie Peters currently works for Astrazeneca, Sweden, in the In vitro PK section of Discovery DMPK & Bioanalytical Chemistry department, as an associate Principal Scientist. After completion of PhD in Chemistry in 1990, she has been in the academia for nearly 10 years before moving to the pharma industry. In 1998 she joined Cyprotex, a biotech company in UK, where she helped develop several models to predict drug distribution and absorption. She has also built a generic Physiologically Based Pharmacokinetic (PBPK) modelling and simulation tool. At Astrazeneca, where she has been employed since 2003, she has had the responsibility to develop and deploy cutting edge computational tools on a common portal accessible to all Astrazeneca’s R&D sites. She has provided scientific input and modelling support to several drug discovery and development projects based at different Astrazeneca R&D sites in Sweden, and worked closely with project leaders to encourage them to benefit from the application of PBPK models.

Chair:

Dr. Steven Bodovitz, Principal, BioPerspectives, USA

Steven Bodovitz, PhD, is a Principal at BioPerspectives, a renowned research and strategy consultancy in San Francisco, California. He is an expert at analyzing markets and developing strategies for the biotechnology industry. He has worked with a range of companies, from start-ups to Fortune 500. He has published a guide on business plan writing for the biotechnology industry, and he has written more than 20 business plans for biotechnology companies encompassing diagnostics, therapeutics and tools. He has written 16 comprehensive market analysis reports on topics ranging from immunoassays to microarrays to proteomics to RNAi therapeutics. He has published articles in Trends in Biotechnology, Drug Discovery Today and Drug Discovery World. He has presented his market analyses at biotechnology conferences in the US, Europe, and Japan, and he has been quoted in Science, Nature Biotechnology and The Economist. In addition to BioPerspectives, Dr. Bodovitz also served as Interim CEO of AminoArrays, an early-stage company with a patented method for array-based amino acid analysis. Dr. Bodovitz took over a company without ongoing product development and without a sound financial position and engineered an international collaboration between the leading low-density microarray platform company and the world’s leading expert in the biochemistry underlying the core technology. Prior to becoming a biotechnology analyst and strategist, Dr. Bodovitz received his PhD in neuroscience from Northwestern University, where he studied the molecular mechanisms of Alzheimer’s disease.

Co-Chair:

Dr. Bin Zhang, Research Fellow, Genetics Department, Merck & Co., USA

Dr. Bin Zhang is a Research Fellow in the Genetics Department at Merck & Co. His expertise lies in bioinformatics and computational biology, pattern recognition and data mining. Dr. Zhang developed a theory for weighted gene co-expression network analysis which has been extensively employed to identify pathways and gene targets involved in a variety of diseases such as cancer, atherosclerosis, Alzheimer's, obesity and diabetes etc. One of such applications was selected as the second most influential brain tumor publication in the year 2006 by the brain tumor research portal. His recent research along this direction has been highlighted by Nature. Dr. Zhang's early research on image pattern recognition significantly contributed to several large-scale pattern recognition systems of national interest. Dr. Zhang has published over 20 journal papers, including a number of high profile papers in Nature, PNAS, and Nature Genetics. Dr. Zhang is the recipient of the Best Paper Award of ICDAR 2003 ─ the Seventh International Conference on Document Analysis and Recognition. Dr. Zhang joined Merck & Co. as a senior research scientist in 2005 and then was promoted as Research Fellow in 2007. Prior to joining Merck & Co., Dr. Zhang was a post-doctoral fellow from 2003 to 2004 and then a Research Faculty and Senior Biostatistician at David Geffen Medical School of University of California at Los Angeles. Dr. Zhang holds a Ph.D. and a master degree in Computer Science from the State University of New York at Buffalo, a master degree in electronic engineering from Tsinghua University, Beijing, China, and a bachelor's degree in electrical engineering from Tongji University, Shanghai, China.

13:30-13:50

Keynote Speech:
Title: The SGC and Chemical Biology - an Open Access Model to Promote the Science of Drug Discovery
Dr. Johan Weigelt, Chief Scientist, Structural Genomics Consortium, Karolinska Institutet, Sweden

13:50-14:10

Title: The Emergence of Multivariate Diagnostics Predicts the Emergence of Multivariate Drug Targets
Dr. Steven Bodovitz, Principal, BioPerspectives, USA

14:10-14:30

Title: Understanding the Mechanism and Detecting Biomarkers of Type II Diabetes with LC/MS Based Metabonomics Technology
Dr. Robert Plumb, Professor, Royal Society of Chemistry, UK

14:30-14:50

Title: Inhibition of Cancer Cell Growth By Genomic Quadruplex Sequences
Dr. Donald M. Miller,Director, James Graham Brown Cancer Center, University of Louisville, USA

14:50-15:10

Title: Integrative Genomics Approaches to Understanding Complex Metabolic Diseases and Identifying Candidate Therapeutic Targets
Dr. Xia Yang, Systems Biologist, Sage Bionetworks, USA

15:10-15:30

Coffee Break

15:30-15:50

Title: The Global Landscape of Human Brain Transcriptional Networks in Alzheimer's Disease
Dr. Bin Zhang, Research Fellow, Genetics Department, Merck & Co., USA

15:50-16:10

Title: Genomics/Pharmacogenomics in Biomarker Discovery and Translational Medicine Studies
Dr. Jason (Gang) Jin, Co-Founder and Executive Vice President of Global Business (CRO) of Shanghai Biochip Co., Ltd (SBC) & CEO of ShanghaiBio Corporation (SBC for Global R&D Services in USA), China

16:10-16:30

Title: Transgenic Approach of Metabolic Engineering in the High-value Medicinal Echinacea Plants
Dr.Kin-Ying To, Associate Research Specialist, Agricultural Biotechnology Research Center, Taiwan.

16:30-16:50

Title: PhosSNP: Systematic Analysis of Genetic Polymorphisms that Influence Protein Phosphorylation
Dr. Yu Xue, Associate Professor, Department of Systems Biology, University of Science & Technology of China, China

Chair:

Dr. James S. Norris, Professor and Chairman, Department of Microbiology and Immunology, Medical University of South Carolina, USA

Dr Norris has had a long-standing interest in the fields of carcinogenesis and gene therapy and has several experimental approaches that are in the late preclinical stages of development. He is well published in both fields. As a researcher, he has received grants from institutions including the American Cancer Society, the National Institutes of Health, and the National Science Foundation and was awarded a Burroughs Wellcome Travel Fellowship, a Fogarty Fellowship (declined), an award from The Brockmann Fund and was funded to develop phage gene therapy by Hexal, Gmb. Since 1998, he has been on the International Society of Cancer Gene Therapy Council, President of the International Society of Cancer Gene Therapy (2005-2006) ; Councilor for the American Society of Microbiology Chairs (2006-2008), and currently, belongs to ASGT and many other societies . He has served on numerous NIH/DOD/ NCI review panels. His research efforts are focused on standard of care therapy of cancer in combination with small molecule inhibitors of sphingolipid metabolism. He is President of the Board and Interim CEO of a biotech company, SphingoGene, Inc.

Co-Chair:

Dr. Julie Jia, Account Manager, Millipore Corporation, USA

Dr. Julie Jia joined Millipore in 2003 as a Drug Discovery Specialist, has presented numerous technical seminars on applications of drug discovery products in hundreds of companies and universities as well as international scientific conferences.  Julie recently advanced closer to the frontline of interaction with clients, became an Account Manger responsible for sales of Millipore’s Bioscience Division products, providing service to biopharmaceutical clients in a training and communication fashion.
Before joining Millipore, Dr. Julie Jia worked in field application/ scientific marketing position for IGEN for 3 years. And prior to that Julie was a research scientist in both biotech and academia working on drug discovery in neuroscience and microbiology research areas, with tracking record of publications.  Julie received her PhD in Cell and Molecular Biology from North Dakota State University and BS degree in Microbiology from Beijing Agricultural University.

13:30-13:50

Keynote Speech:
Title: The Human Pituitary: Nitroproteins and Pathway Analysis
Dr. Dominic M. Desiderio, Professor, University of Tennessee Health Science Center, USA

13:50-14:10

Title: “Complement”-Ary Vaccines?
Dr. Heribert Stoiber, Professor, Department of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria

14:10-14:30

Title: Personalized Medicine as a Possibility in Cancer Gene Therapy
Dr. James Scott Norris, Professor and Chairman, Department of Microbiology and Immunology, Medical University of South Carolina, USA

14:30-14:50

Title: Metabolic Biomarkers Discovery Project
Dr. Vladimir Tolstikov, Director, The UC Davis Genome Center, Member of ACS and ASMS, USA

14:50-15:10

Title: Cathepsin S as a Biomarker and Drug Target for Hepatocellular Carcinoma.
Dr. Lang Zhuo, Principal Research Scientist, Institute of Bioengineering and Nanotechnology, Singapore

15:10-15:30

Coffee Break

15:30-15:50

Keynote Speech:
Title: Adenosine A1 Receptor Antagonists for the Treatment of Acutely and Chronic Heart Failure- From Bench to Bedid
Dr. Berthold Hocher, Senior Clinical Research Director, Solvay Pharmaceuticals, Germany

15:50-16:10

Title: Multiplexing Technology to Measure “Biomarkers” in Biological Fluids.
Dr. Julie Jia, Account Manager, Millipore Corporation, USA

16:10-16:30

Title: Micro-SPECT and PET Imaging Study in Drug Discovery
Dr. Yu-Mei Shen, Professor, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, China

16:30-16:50

Title: Identifying Acid Ceramidase as a New Protein Biomarker Candidate That May Lead to Better Diagnosis of Tumor Aggressiveness and Improved Treatment for Head and Neck Cancer
Dr. Xiang Liu, Assistant Professor, Department of Microbiology and Immunology, Medical University of South Carolina, USA

Chair:

Dr. Martina Uray, Researcher, Joanneum Research - Institute of Digital Image Processing, Austria

Martina Uray was awarded a M.Sc. in Technical Mathematics (branch Techno-Mathematics) in 2003 by the Graz University of Technology for her master thesis "A mathematical model for automatic punch-typing in immunhistochemistry (TMA-Analysis)". At the Institute for Computer Graphics and Vision (branch Informatics, also TU-Graz) she received a Ph.D. in 2008 for her dissertation "Incremental, Robust, and Efficient Linear Discriminant Analysis Learning". Her areas of interest are medical imaging, biometrics, object recognition and learning. In September 2008 she joined the JOANNEUM RESEARCH Institute of Digital Image Processing where she became head of the field "human-centered image processing". Martina Uray has already published 14 papers within her scope of research.

Co-Chair:

Dr. Hsin-Yun HSU, Research Scientist, Kazusa DNA Research Institute, Japan

She has written a book chapter "Miniaturized multiplex immunoassays "in “Clinical proteomics: Methods and Protocols” (2008). Recently, in the review “Multiplex microsphere-based flow cytometric platforms for protein analysis and their application in clinical proteomics - from assays to results”, in ELECTROPHORESIS (Oct. 2009 in press), she demonstrates the potential of bead-based platform in clinical diagnosis as well as unmet needs, trends and regulations of the technologies. In addition, she co-authored with Dr. Jutta Bachmann (project manager of www.biochipnet.de) and Dr. Thomas Joos in the book “Reverse Chemical Genetics: Protein microarrays – effective tools for the study of inflammatory diseases” (2009).

Chair:

Dr. Burton Yang, Professor, Dept of Laboratory Medicine and Pathobiology, University of Toronto, Canada

Dr. Burton Yang received his Ph.D. degree from the University of Manitoba in 1992, followed by a postdoctoral training in Manitoba Institute of Cell Biology. He moved Harvard Medical School for a second postdoctoral training in 1993. Dr. Yang took a position as a scientist in Sunnybrook Health Sciences Centre and an assistant professor at the Department of Laboratory Medicine and Pathobiology, University of Toronto in 1995. He was promoted to associate professor in 2001 and professor in 2007. Dr. Yang is currently a Career Investigator for Heart and Stroke Foundation of Ontario. Dr. Yang’s group has been working on the extracellular matrix, especially in the area of proteoglycan. Dr. Yang’s group undertakes the approaches of RNA interference including siRNAs and microRNAs to study the roles of matrix molecules in angiogenesis. It now appears that some of the microRNAs discovered in the human genome contribute to the development of cancer. Dr. Yang has developed a system to study the role of microRNA in tumor growth and angiogenesis in vitro and in vivo. His group has demonstrated that one of the microRNA (miR-378) enhanced tumor cell survival and tumor growth. They have also showed that expression of versican 3’untranslated region modules organ adhesion in transgenic mice. Further more, transgenic mice expressing miR-17 are shown to grow slower and fibronectin appears to be a target associated mediating miR-17 functions. Dr. Yang’s group is studying the mechanism associated with this effect.

15:30-16:00

Title: MicroRNA miR-17 Retards Tissue Growth and Represses Fibronectin Expression
Dr. Burton Yang, Professor, Dept of Laboratory Medicine and Pathobiology, University of Toronto, Canada

16:00-16:30

Title: MicroRNA Regulation of Oncolytic Herpes Simplex Virus Type 1 for Selective Killing of Prostate Cancer Cells
Dr. William Wei-guo Jia, Associate Professor, University of British Columbia, Canada

16:30-17:00

Title: Schistosoma japonicum: Evaluation of an RNAi-based Treatment Targeting Gynaecophoral Canal Protein Gene
Dr. Guofeng Cheng, Professor, Chinese Academy of Agricultural Sciences, China

Chair:

Dr. Michael Markert, Principal Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Michael Markert is the Principal Scientist and Lab-Head cardiovascular safety of General Pharmacology in Boehringer Ingelheim Pharma GmbH & Co KG.. Being a Biologist, trained surgeon/anesthetist, he received ECG/cardiovascular education in College of Veterinary Medicine at Ohio State University, Columbus, US and his mentor was Prof. Robert Hamlin. He has been working for 15 years in the field of Telemetry Research. also, in 2005 and 2009, he worked in  the program committee of Safety Pharmacology Society while in 2006,2008 and 2009 he joined the society as a speaker. In 2008, he received BI German Research Award.

Co-Chair:

Dr. Taosheng Chen, Director, High Throughput Screening, St. Jude Children's Research Hospital, USA

Taosheng Chen received his BS degree in biophysics from Fudan University in Shanghai. He earned his MS degree in molecular cell biology, also from Fudan University, studying the anticancer properties of parvoviruses with Dr. Zuyu Luo. He received his PhD in cell and molecular biology from the University of Vermont, working with Dr. Janet Kurjan on desensitization of the yeast pheromone response pathway, a GPCR – MAP kinase pathway. He conducted postdoctoral studies with Dr. Michael Weber at the University of Virginia, studying the role of Ras to MAP kinase pathway and of the androgen receptor in prostate cancer progression. Between 1998 and 2000, he worked as a research scientist at SAIC-Frederick, National Cancer Institute. From 2000 to 2006, Dr. Chen was a senior research investigator in the Lead Discovery and Profiling Department at Bristol-Myers Squibb, where he was responsible for various aspects of drug discovery, including assay development, HTS, HCS, new technology evaluation and development, and drug–drug interactions. Taosheng has also been certified as a PMP (Project Management Professional) by the Project Management Institute. Taosheng joined the faculty of the Department of Chemical Biology and Therapeutics (CBT) at the St. Jude Children's Research Hospital in 2006. His laboratory focuses on studying the regulation of transcription factors and their implications in drug metabolism and drug resistance as well as in pediatric cancers.  He has also been the director of the St. Jude HTS Center, and its members work together with St. Jude researchers to discover and develop new chemical entities as tools for translational research or as therapeutic leads for the treatment of catastrophic pediatric diseases. The center employs state-of-the-art automation and assay technologies, and an onsite library of 525,000 compounds. In addition, it is developing the whole-genome RNA-interference technology. Dr. Chen has authored more than 20 peer-reviewed articles in the areas of cancer biology, drug metabolism, signal transduction, and drug discovery technology. He serves as a section editor for Current Chemical Genomics. The book he edited, “A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery”, will be published by CRC Press-Taylor and Francis Group, LLC in late 2009.

Chair:

Dr. Oleg Targoni, Director of Laboratory, GLP, Cellular Technology Ltd., USA

Oleg Targoni, male, immunologist, graduated from Kharkiv University, Ukraine in 1978, and received his Ph.D. at Moscow State University in 1994. He worked at the Institute of Biochemistry at the Russian Academy of Science in Moscow, and - following his move to the US in 1995 - at the Department of Pathology at Case Western Reserve University in Cleveland, OH. Since 2001, he has been the Laboratory Director at Cellular Technology Limited, Cleveland, OH. There, he oversees the GLP Laboratory operations and conducts CRO projects as Study Director.

Co-Chair:

Dr. Frank Fan, Senior Research Manager, Promega Corporation, USA

Dr. Frank Fan is a Senior Research Manager at Promega Corporation.  He is responsible for developing novel technologies in luciferase reporter and other luminescent detection methods.  Prior to joining Promega in 2002, he has worked at GlaxoSmithKline for five years and was a Senior Investigator in anti-infectives drug discovery.  Dr. Fan received his B.S. in Biology from Nankai University in China and  Ph.D. in Biochemistry from the University of Iowa.  He did his postdoctoral training in the Department of Molecular Biology and Biophysics at Yale University.  Dr. Fan is a Conference Committee member for the Society of Biomolecular Science.  He has served as organizing chair and session chair and for scientific conferences including the 2008 SBS Cell-based Assay Symposium in US.  Dr. Fan has authored more than 20 peer-reviewed papers, book chapters and is an inventor for several patents.  Dr. Fan serves as regular or ad hoc editor for several journals including Assays and Drug Discovery Technologies, Current Chemical Genomics, Microbial Biotechnology and Journal of Bacteriology.

Chair:

Dr. Steven Hayes, Director, BellBrook Labs, LLC, USA

Dr. Hayes received his Ph.D. in 1997 from the University of Illinois at Chicago studying mammalian cell cycle regulation and tumor suppressor proteins.  Post-doctoral studies at Stanford and Northwestern Universities focused on signal transduction in prostate cancer, including the effect of putative chemopreventatives on biomarkers in clinical trials.  As principal scientist and later research area manager at Panvera/Vertex Pharmaceuticals, Dr. Hayes led a variety of assay development projects including custom assay development services.  He is now Director of R&D at BellBrook Labs, which is focused on developing more predictive assay technologies for drug discovery.

Co-Chair:

Dr. Paul Orange, Bio-discovery Business Leader – APAC, PerkinElmer, China

Dr. Orange received his Ph.D. In 1997 from the University of Sheffield, UK, studying the molecular biology of aminergic receptors in Schizophrenia. After post-doctoral work at the Wellcome Centre for Cell Matrix research in Manchester, UK, Dr. Orange moved to the (then) Amersham Pharmacia Biotech, where he worked in proteomics technologies R&D. After a period of time working for a UK start-up company as senior product manager, Dr. Orange joined PerkinElmer as global product manager for the Live Cell Imaging product line, later becoming strategic development leader for the newly formed Cellular Imaging and Analysis business, which includes products for acquisition, analysis and storage of cellular image data used both in early research and drug screening studies. Dr. Orange is responsible for PerkinElmer’s Bio-discovery products across the Asia-Pacific region.

13:30-14:00

Title: High Throughput Innovative Technologies for Physical form Selection and Drug Delivery System to Get Faster into Clinic
Dr. Sudhakar D. Garad, Group Head-Formulation, Novartis Institutes for Biomedical, USA

14:05-14:35

Title: Adapting Functional Assays and Advanced Cell Models to Existing HTS Automation
Dr. Steven Hayes, Director, BellBrook Labs, LLC, USA

14:35-15:10

Title: High Content Screening Image Capture, Analysis and Storage - Considerations for Success
Dr. Paul Orange, Bio-discovery Business Leader – APAC, PerkinElmer, China

15:10-15:20

Coffee Break

Chair:

Dr. Michael B. Bolger, Chief Scientist and Director of Life Sciences, Simulations Plus, Inc., USA

Upon completion of his doctorate in Pharmaceutical Chemistry from the University of California at San Francisco in 1978 he joined the faculty of Pharmaceutical Sciences at the University of Southern California (USC) School of Pharmacy where he conducted research and teaching in medicinal chemistry and the computational aspects of drug discovery and development for 23 years. From 1987-1993, simultaneous with his academic duties, he was a founder and Director of Medicinal Chemistry at CoCensys Inc. There, he studied the chemistry and use of novel neuroactive steroids for treatment of anxiety, epilepsy, and sleep disorders. Drug candidates emanating from seven of his patents have been tested in Phase I and II clinical trials for petite mal epilepsy, sleep disorders, and migraine. As a faculty member at USC School of Pharmacy, his research was supported by several NIH basic science research grants and he published over 50 peer-reviewed publications. Currently, as Chief Scientist at Simulations Plus, Inc. (Lancaster, CA), he oversees a team of scientist / programmers at in the development of software programs (ADMET Predictor/Modeler, ClassPharmer, GastroPlus, DDDPlus, and MembranePlus) for estimation of biopharmaceutical properties, simulations of absorption and bioavailability, automated generation QSP/AR model building, in vitro dissolution, and cell culture permeability simulation. He was elected to the rank of Fellow of the American Association for the Advancement of Science in 1996.

Co-Chair:

Dr. Hai Wei, Associate Professor, Center for Chinese Medical Therapy and System Biology, Shanghai Unviversity of Traditional Chinese Medicine, China

Dr. Hai Wei holds a BSc in pharmacy from Shenyang Pharmaceutical University in China. He received his M.S. and Ph.D. in Biopharmaceutics from University of Alberta in Canada in 2000 and 2006. In the meanwhile, he worked as analyst and scientist in Enviro-Test Laboratories (Canada) and Merck Frosst Canada. He joined the Shanghai University of Traditional Chinese Medicine in 2007. His research interests are in formulation development and evalution of the oral performance of Traditional Chinese Medicine. In the past years, he has consulted different pharmaceutical and nutraceutical companies in their product development and helped them to set product specifications. The application of nanotechnology for drug delivery system is another major research interest, especially for the high potent drugs. He is the member of the American Association of Pharmaceutical Scientists; He is the committee member of Traditional Chinese Medicine in Pharmaceutics (World Foundation of Chinese Medicine Science).

08:30-08:55

Keynote Speech:
Title: How to Improve the Widespread Use of Modeling and Simulation in Drug Discovery and Development
Dr. Michael B. Bolger, Chief Scientist and Director of Life Sciences, Simulations Plus, Inc, USA

08:55-09:20

Title: CNS Availability Predicted by Brain Membrane Affinity, PSA, and Plasma Protein Binding
Dr. Hinnerk Boriss,CEO, Sovicell GmbH, Germany

09:20-09:45

Title: Application of Computational Systems Biology for Discovery and Safety Analysis of New Anti-inflammatory Drugs
Dr. Oleg Demin, CSO, Institute for Systems Biology SPb, Russia

09:45-10:10

Title:Predicting Kinetic Parameters Km and Vmax for Substrates of Human Cytochrome P450
Dr. Jinhua Zhang, Senior Scientist, Simulations Plus, Inc., USA

10:10-10:30

Coffee Break

10:30-10:55

Title: An in Silico Model for Simulation and Assessment of Sublingual Drug Delivery Experience with Sublingual Propranolol
Dr. M.S.S. Chow, Professor & Director, Western University of Health Sciences, USA

10:55-11:20

Title: Computationally Designed Myxoma Virus Peptide as a Candidate for Cancer Therapy
Dr. Taghrid Istivan, Research Fellow, School of Applied Sciences, Health Innovations Research Institute, RMIT University, Australia

11:20-11:45

Title: Development of In Vitro/In Vivo Correlations Based on the Biopharmaceutics Drug Classification System
Dr. Hai Wei, Associate Professor, Center for Chinese Medical Therapy and System Biology, Shanghai Unviversity of Traditional Chinese Medicine, China

11:45-12:10

Title: Pharmacophore Ensemble/Support Vector Machine: A Novel Scheme to Address Protein Plasticity without Protein Structure
Dr. Max Leong, Assistant Professor, National Dong Hwa University, Taiwan

Chair:

Dr. Xian-Ming Zeng, Senior Director, Global Respiratory R&D, TEVA Pharmaceuticals, USA

Dr. Zeng obtained his PhD in Pharmaceutical Sciences from King’s College, University of London in 1997 and upon completion, was appointed the prestigious Maplethorpe Post-doctoral Fellow. Dr. Zeng joined IVAX in 1999 and was responsible for developing a novel Multi-dose dry powder inhaler, the SpiromaxTM. After leaving IVAX in 2006, Dr. Zeng took up the position of Professor of Pharmaceutics and Director of Research at Medway School of Pharmacy, Universities of Kent and Greenwich, UK. Dr. Zeng now serves as Senior Director, Global Respiratory R&D of TEVA Pharmaceuticals. Dr. Zeng has published extensively in peer-reviewed journals on inhalation formulation and device technologies as well as in vitro characterization of inhalation products. He is a co-author of a textbook and a co-inventor of a number of patents and patent applications. Dr. Zeng is a visiting professor of King’s College, University of London in the UK and Xi’an Jiaotong University of China. He is also a board member of International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS).

Co-Chair:

Dr. Motoichi Kurisawa, Principal Research Scientist, Institute of Bioengineering and Nanotechnology, Singapore

Motoichi Kurisawa received his Ph.D. degrees from the School of Materials Science, Japan Advanced Institute of Science and Technology (JAIST) in 1998. He conducted his postdoctoral experiences in the area of biomaterials at Tokyo Women’s Medical University and Kyoto University. He joined Institute of Bioengineering and Nanotechnology (IBN) in 2003, and is currently Team Leader and Principal Research Scientist. His research interest is biomaterials for dug delivery and tissue engineering.

08:30-08:55

Keynote Speech:
Title: Iron Oxyde Nanocrystals for Cancer Therapy: In Vitro and in Vivo Studies
Dr. Laurence Motte, Professor, Laboratoire CSPBAT FRE 3043 CNRS, Université Paris 13, France

08:55-09:20

Title: Topical Delivery of Peptides Using Novel Nanostructured Lipid Carrier Nanoparticle (NLCN) System
Dr. Mandip Singh Sachdeva, Professor, Florida A&M University, USA

09:20-09:45

Title: Inhalation as a Delivery Paradigm for Local and Systemic Therapies
Dr. Xian-Ming Zeng, Senior Director, Global Respiratory R&D, TEVA Pharmaceuticals, USA

09:45-10:10

Title: Enzyme-Mediated Injectable Hydrogel System for Drug Delivery and Tissue Engineering
Dr. Motoichi Kurisawa, Principal Research Scientist, Institute of Bioengineering and Nanotechnology, Singapore

10:10-10:30

Coffee Break

10:30-10:55

Title: QPatch - Bringing Patch Clamping Further
Dr. Morten Rytter Sunesen, Vice President, Sophion Bioscience A/S, Denmar

10:55-11:20

Title: Safe and Efficient Nucleic Acid Carriers
Dr. Asier Unciti-Broceta, Research Investigator, School of Chemistry, University of Edinburgh, UK

11:20-11:45

Title: The Role of Especiality Excipients in Oral Drug Delivery Systems
Dr. Catherine Zhu, Formulation Technologies Manager, Colorcon, China

11:45-12:10

Title: 3D Human Elastin-like Based Matrices as Potential Drug Delivery System
Dr. Antonella Bandiera, Assistant Research, Department ο f Biochemistry, Biophysics and Miclomolecular Chemistry, University οf Trieste, Italy

Chair:

Dr. Niek Dekker, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca, Sweden

Niek Dekker got his PhD in enzymology in 1991 at Utrecht University, the Netherlands, on structural studies of pancreatic phospholipase A2 and its inhibitor micelle complexes with NMR. He moved into structural biology as a postdoc in NMR spectroscopy and determined the solution structure of the POU DNA binding domain of the Oct-1 transcription factor in 1992, followed by an EMBO fellowship at the ETH Zurich, Switzerland on site-directed mutagenesis. He was Assistant professor in membrane enzymology at Utrecht University from 1994-2000 with focus on functional, biophysical and structural studies of membrane enzymes. The research resulted in an extensive understanding of membrane regulation of protein function, and led to the crystal structures of two prokaryotic outer membrane enzymes, elucidated in collaboration with crystallography groups. Dekker has authored more then 50 peer-reviewed publications in the area of biochemistry. In 2000 he moved to AstraZeneca to lead the Protein Engineering team in the Structural Chemistry Laboratory. Focus in his team was on the production of crystallization-grade human proteins for structural studies by NMR and crystallography. In 2004 he became Associate Director, and in 2008 he moved into a project management role coordinating bioreagent and structure support from the global organization for CNSP.

Co-Chair:

Dr. Hua-fen Liu, Senior Scientist, Applied Biosystems, USA

Upon completion of her master thesis from Sack’s lab in chemistry at University of Michigan, Hua-fen joined DMPK department in Parke-Davis (Pfizer, Ann Arbor) and then followed by Roche, Palo Alto. She joined Applied Biosystems as Sr. Scientist in 2007 after over 10 years of pharmaceutical industry working experience.
She has extensive hands-on experience and in depth knowledge on LC-MSMS triple quadrupole, ion trap and their applications in different in vitro, in vivo biological matrixes and diagnostic clinical sample matrix in GXP and non-GXP settings. She is one of the contributors in development of LC-MSMS software for drug discovery and development (DiscoveryQuant and LightSight).  She also has board experience and sound knowledge of fundamental principles in drug metabolism for drug discovery and development.  She designed, implemented and managed early ADME assays including permeability, transporter mechanism studies, CYP inhibition, definitive in vitro drug-drug interaction and metabolite ID for clinical candidates. Hua-fen has published over 30 posters and papers.

Chair:

Dr. Danhua Chen,Associate Director, Analytical Sciences, R&D, TEVA Pharmaceuticals, USA

Dr. Danhua Chen obtained his Ph.D. in Chemistry from Wuhan University in 1988 and Ph.D. in Biotechnology from University of Wisconsin-Madison in 1995. He is Associate Director of Analytical Sciences at TEVA Pharmaceuticals USA in Irvine, California site. He was a Senior Principal Scientist at Department of Research Science and Technology, Pfizer Global Research & Development, Pfizer, Inc. from 2003 to 2009.  He has been working on the drug research and development for 15 years. He contributed to successfully develop 3 drugs to international market and advanced many drug candidates in different stages of pre-clinical, clinical development to the next phase. Dr. Chen has 41 publications (research paper, review articles) in international, peer-reviewed Journals, 2 patents, one book chapters and about 17 awards.

Co-Chair:

Dr. Pardeep K. Gupta, Associate Professor, University of the Sciences in Philadelphia, USA

Dr. Pardeep K. Gupta is an Associate Professor of Pharmaceutics in Philadelphia College of Pharmacy at the University of The Sciences in Philadelphia (USP). He received his B. Pharm. and M. Pharm. (pharmaceutical chemistry) degrees from India. He also received a M.S. degree in medicinal chemistry from USP and his Ph.D. in pharmaceutics from University of Wisconsin. His research interests include delivery of proteins and peptides and study of the interaction of drugs with biomembranes. He has published several articles and has authored several book chapters. His teaching responsibilities include courses in solubility, controlled drug delivery and drug stability at the graduate level. He is on the editorial board of Remington: The Science and Practice of Pharmacy, and is the editor of Pharmaceutical Chemistry and Pharmaceutical Testing, Analysis and Control sections of the book.

Chair:

Dr. Srinubabu Gedela, Director, OMICS Publishing Group, Research Affiliation-Stanford University School of Medicine, USA

Srinubabu Gedela has completed his Ph.D at the age of 25 years from Andhra University. He is the founder of OMICS Publishing Group, a premier quality open access publisher for the advancement of science and technology and director of GSB Life Sciences, a premier Bio-Soft service organization. He has published more than 25 papers in reputed journals and serving as an editorial board member of repute.

Co-Chair:

Dr. Heleen M. Wortelboer, Senior Project Leader, TNO Quality of Life Biosciences, The Netherlands

Dr. Heleen Wortelboer received her Masters of Science degree in biology in 1987 from the University of Utrecht in The Netherlands. During her studies she performed research projects on oxygen radicals (Free University, Amsterdam), physiology/endocrinology (Free University, Amsterdam), and biological toxicology (University of Utrecht). She received her PhD in Biology and Toxicology in 1991 from the University of Utrecht, working in a collaboration project between TNO, Institute of Risk Assesment, and National Institute for Public helath and Environment (The Netherlands).  Since 2000, she works as a Senior Scientist and Project Leader within the PharmacoKinetics and Metabolism team at TNO, The Netherlands Organization for Applied Scientific Research, a non-for-profit research and technology organization that makes innovation possible by translating scientific knowledge into practice. Research interests include bioavailability and biodistribution of compounds with special focus on metabolizing enzymes and active transporters. She is involved in research and GLP-related studies in close cooperation with various pharmaceutical companies in projects related to especially in vitro bioavailability, metabolism, and active transport of food compounds and drugs.

Chair:

Dr. Ajay K. Banga, Professor and Chair, Department of Pharmaceutical Sciences, Mercer University, USA

Dr. Ajay K. Banga is Professor and Chair in the Department of Pharmaceutical Sciences at the College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA, USA. His research expertise is in non-traditional approaches for transdermal drug delivery, especially for water soluble drugs including small conventional molecules and macromolecules. Dr. Banga has a Ph.D. in pharmaceutics from Rutgers University, NJ. He is currently major advisor to 10 Ph.D. students and has graduated 15 students under his guidance. His laboratory is funded by several start up and leading pharmaceutical companies. Dr. Banga currently serves on the Editorial Board of 6 journals and has served as the Editor-in-Chief (2002-07) for a drug delivery journal. He has written two books in the areas of delivery of proteins and transdermal delivery. He has served on over 30 thesis/dissertation advisory committees and as a referee for over 28 journals. He is a Fellow of the American Association of Pharmaceutical Scientists.

Co-Chair:

Dr. Jianshe Yang, Associate Professor, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, China

Dr. Yang obtained his PhD from Institute of Modern Physics, Chinese Academy of Sciences (IMPCAS) in 2005, and was appointed the assistant professor, associate professor in 2005 and 2007 in the IMPCAS and LICPCAS, separately. During 2006-2008, he worked in the Shanghai Institute of Applied Physics of Chinese Academy of Sciences (SINAPCAS) as a postdoctor, engaged in radiobiological application of nano materials. Dr. Yang have accepted the outstanding postdoctor award from China Postdoctoral Science Fundation and Wong Kuancheng Foundation of Hongkong, published more than 20 peer-reviewed articles in the worldwide journals.

09:50-10:10

Keynote Speech:
Title: New Technologies to Allow Transdermal Delivery of Therapeutic Proteins and Small Water Soluble Drugs
Dr. Ajay K. Banga, Professor and Chair, Department of Pharmaceutical Sciences, Mercer University, USA

10:10-10:30

Title: A Magnetic Organic Complex with Anti-tumor Properties for Controlled Drug Delivery and Magnetic Resonance Imaging
Dr. Haruki Eguchi, Senior Researcher, IHI Corporation, Japan

10:30-10:50

Title: Looking for an New Radiosensitizer from Carbon Nanotubes
Dr. Jianshe Yang, Associate Professor, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, China

10:50-11:10

Title: Monodisperse Chitosan Microspheres with Interesting Structures for Proein Drug Delivery
Dr. Lian-Yan Wang, Assistant Research Fellow, Institute of Process Engineering, Chinese Academy of Sciences, China

11:10-11:30

Title: The Effect of Glycoside Clathration. Creation of New Low-dose Drugs
Dr. Arkadiy Bryzgalov, Researcher Follow, N.N.Vorozhtsov Institute of Organic Chemistry Siberian Branch of RAS, Russia

11:30-11:50

Title: CD-44 Targeted Therapy as an Innovative Strategy for Anticancer Drug Delivery
Dr. Annalucia Serafino, Researcher, INMM-ARTOV, National Research Council, Italy

11:50-12:10

Title: PEGylated Proliposomes: Improved Oral Drug Delivery Systems
Dr. Praveen S. Hiremath, Scientist, Product Development, Pharmaceutics International, Inc., USA

12:10-12:30

Title: Novel Particulate Drug Delivery Systems by Recrystallized Agglomeration Technique
Dr.Adhikrao Yadav,Principal and Professor of pharmaceutics, Biopharmaceutics Research Group, Department of Biopharmaceutics, Govt. College of Pharmacy, India

Chair:

Dr. Martin H. Bluth, Director of Translational Research, Wayne State University School of Medicine, USA

Dr. Martin Bluth, joined the Wayne State University School of Medicine as an Associate Professor in the Department of Pathology, serves as Director of Translational Research for the Department of Pathology, and Associate Director of the Transfusion Service for the Detroit Medical Center ; both of which are based in Detroit, Michigan USA . His areas of research include immunology, inflammation, pancreatology, biomarker discovery, glycolipid based anti-inflammatory therapy, role of IgE in viral diseases and cancer, and blood derived stem cell propogation. He is also the founding editor / editor in chief of the Journal of Pharmacogenomics and Personalized Medicine (Dove Medical Press) He holds more than 15 new inventions and technologies, many of which are patent pending. Dr. Bluth is also Vice President of BioMedica Management Corp., and on the Board of Directors of FirstPoint Biotech venture fund. He has recently pioneered biomarker discovery platforms for use toward clinical applications and entrepreneurial start-up companies.

13:30-13:55

Keynote Speech:
Title: Biomarker Discovery Platforms in Pharmacogenomics and Personalized Medicine
Dr. Martin H. Bluth, Director of Translational Research, Wayne State University School of Medicine, USA

13:55-14:20

Title: The Identification and Application of Biomarkers in Inflammatory Diseases
Dr. Chris Chamberlain, Global Head Medical Genetics, Disease Biology Area Biomarker Expert,                    Roche Products, UK

14:20-14:45

Title: Multiplex Diagnostics: Opportunities and Challenges for Revenue
Dr. Bruce Quinn, Formerly the Contractor Medical Director, California Medicare, USA

14:45-15:05

Coffee Break

Chair:

Dr. Robert G Fassett, Professor, Central Clinical Division, School of Medicine, The University of Queensland, Australia 

Academic Appointments: Professor, Central Clinical Division, School of Medicine The University of Queensland and Director of Renal Research, Senior Staff Specialist, Renal Medicine, Royal Brisbane and Women’s Hospital Brisbane Queensland. I am a Foundation Fellow of the American Society of Nephrology. Previously, Professor of Medicine, University of Tasmania
Research: I am currently undertaking over 30 research projects, half of which are investigator-initiated studies. I have established research collaborations with the Schools of Human Life Sciences, Nursing and Psychology at the University of Tasmania and with the School of Human Movement Studies at the University of Queensland. I have published 64 original articles with 497 citations and have an H-index of 12. I have had presentations accepted at the American Society of Nephrology Meetings each year since 2000. Research undertaken on Morning Report (Clinical handover) has been incorporated into guidelines and research on urinary red blood cell morphology has contributed to current recommendations for the investigation of hematuria. I completed a PhD in October 2008 at the University of Queensland on the Effect of Atorvastatin on the Progression of Chronic Kidney Disease. 

Co-Chair:

Dr. Ling Tao, Professor, Department of Cardiology, Xi-Jing Hospital, The Fourth Military Medical University, China

Dr. Ling Tao received her MD degree in the Fourth Military Medical University, Xi’an, China. She became a full professor of cardiology in FMMU in 2008. She received three NSFC grants in the research of mechanisms of ischemic cardiomyocytes death and protection, two major grants from Chinese National Department of Science and Technology in the new drug innovation field. She also received a National High Technology Research and Development Program (“863” Program) of China in the field of developing a human plasma biomarker for patients with metabolic syndrome. She received totally more than RMB $ 5 million funding support in 2008. She has published 27 peer-reviewed papers in the leading journals in cardiovascular medicine and pharmacology field, including PNAS, Circulation, Circulation research, Diabetes, British Journal of Pharmacology, etc. She is also the invited ad hoc reviewer of journals including Diabetes, Am J Physiol, Lab Invest and so on.

Chair:

Dr. David Deperthes, CEO and President, Med Discovery SA, Switzerland

Founder and CEO of Med Discovery, Dr. Deperthes obtained his Ph.D. in Onco-Urology from Laval University in Canada. Discoverer of a new prostate cancer marker, the kallikrein hK2, he specialized in the development of new molecules and technology platforms for tumor targeting at the prestigious Swiss Institute for Experimental Research on Cancers (ISREC) in Lausanne (Switzerland). Then Dr. Deperthes became Director of the Urology Research Unit at the University Hospital of Lausanne for 5 years. In 2002, he created Med Discovery in 2002 with medical doctors and researchers to develop new drugs for onco-uological cancers. Dr Deperthes is also founder of the International Symposium on Kallikreins and is involved in different committees for Biotechs and new high companies. He also gives lectures for licensing and business opportunities in different universities.

Co-Chair:

Dr. Dage Liu, Assistant Professor, Second Department of Surgery, Faculty of Medicine, Kagawa University, Japan

After graduated from Liaoning Medical University, Liaoning, China in 1989, Dr. Liu joined the Department of Thoracic Surgery at the Chest Hospital of Benxi Iron & Steel Co. (Liaoning, China), a chest surgeon treating with lung cancer patients. From 1994, Dr. Liu performed an experiment study on bronchoplasty at the Second Department of Surgery, Kagawa University, Kagawa, Japan. From 1999, in cooperation with Dr. Huang, Dr. Liu began to be engaged in the cancer research using molecular biology as an Assistant Professor, Kagawa University. Dr. Liu performs many clinical studies on various tumor-associated biomarkers, including the p53-associated pathway (Liu et al, 2002; Masuya et al. 2006) and metastatic suppressor genes (Liu et al. 2001; Huang et al. 2004). Furthermore, Dr. Liu revealed that the Wnt overexpression could promote the tumor progression in human lung cancer (Huang et al. 2005; Liu et al. 2007). Based on these clinical results, Dr. Liu is performing experimental studies on the cancer gene therapy using CD9-inducing vectors (Huang et al. 2006) and Wnt-inhibiting vectors.
.

Chair:

Dr. Pedro Pesini, Head of Laboratory, Araclon Biotech Ltd, Spain

Born in July 24th 1957. PhD in Veterinary Science (1985). Associate Professor in Veterinary Anatomy and Embryology since 1987 until 2007 at the University of Santiago de Compostela (Spain) where combined teaching and research dedication. Main areas of research are neuroanatomy and neurology, neurotransmitter system, brain aging and animal models of Alzheimer disease. In 2007 moved to Araclon Biotech Ltd. with a position as Head of the Laboratory. Our company is primarily devoted to research and develop therapies and diagnostic methods for degenerative diseases.

Co-Chair:

Dr. Hemant Sarin, Research Fellow, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, USA

Dr. Hemant Sarin graduated from medical school at the University of Rochester, USA in 1999. Dr. Sarin trained in neurosurgery at the Universities of Colorado and Pittsburgh, USA until 2003, and then came to the National Institutes of Health (NIH), USA in 2004. Over the past few years, using a dynamic contrast-enhanced MRI approach, he has developed an innovative strategy for effective drug delivery across the pathologic blood-brain barrier (BBB) of brain cancer microvasculature based on his two recent discoveries, with the first being that the physiologic upper limit of pore size in the tumor barrier of cancer microvasculature is approximately 12 nanometers, and the other being that the optimal size range of nanoparticles for drug delivery across the tumor barrier is between 7 to 10 nanometers. Over the course of his fellowship training, Dr. Sarin has received several prestigious NIH research awards, which include the Fellows Award for Research Excellence (FARE) in 2006 and in 2007, and the Novel Experimental Research Development (NERD) Award in 2008. One of Dr. Sarin’s future research goals is to develop, in collaboration with industry, novel imageable nanoparticle-based therapeutics within the 7 to 10 nm size range for the treatment of brain and central nervous system cancers, as well as, for the treatment of other neuropathologies in which the BBB becomes porous

Chair:

Dr. Tao Wang, Principal Scientist, AstraZeneca, USA

Dr. Tao Wang received his BS in Chemistry from University of Science and Technology of China in 1994 and obtained his Ph.D. in Organic/Medicinal Chemistry from State University of New York at Stony Brook in 1999.  After completing his post-doctoral research at Columbia University in the City of New York and a brief stint with 3-Dimensional Pharmaceuticals (now a subsidiary of Johnson and Johnson), Dr. Wang joined AstraZeneca R&D Boston in 2002 and currently holds the title of Pricipal Scientist. He has been working in cancer research area and has played a leading role in discovering a number of clinical candidates for AstraZeneca.

Co-Chair:

Dr. Hugo ten Cate, Professor, Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, The Netherlands

13:30-13:50

Title: Improvement of Paclitaxel by Reformulation via Nanoemulsion
Dr. King Lee, Vice President, Regulatory/Clinical Affairs, Cornerstone Pharmaceuticals, USA

13:50-14:10

Title: Discovery of Potent, Selective Trk Kinases Inhibitors for Treatment of Cancer
Dr. Tao Wang, Principal Scientist, AstraZeneca, USA

14:10-14:30

Title: Target Discovery for Anti-cancer Small Molecule and Antibody Drugs
Dr. Hitoshi Matsushime, Director, Astellas Pharma Inc., Japan

14:30-14:50

Title: Cellular Effects of Anticoagulants: Potential in Cancer Treatment?
Dr. Hugo ten Cate, Professor, Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, The Netherlands

14:50-15:10

Title: Discovery of Novel NFkB and AP-1 Inhibitors as Anti-cancer Agents
Dr. Rajan S. Giri, Department of Medicinal Chemistry, University of Minnesota, USA

15:10-15:30

Coffee Break

15:30-15:50

Title: In Vitro and in Vivo Development of New Anticancer Drugs Selectively Targetting the Multidrug Transporters ABCG2 and ABCC1
Dr. Attilio Di Pietro, Director, Institute of Biology and Chemistry of Proteins, CNRS-University Lyon, France

15:50-16:10

Title: New Antiangiogenic Therapy Proposed for Early Stage Breast Cancer
Dr. Michael Retsky, Lecturer in Surgery, Harvard Medical School, USA

16:10-16:30

Title: A Novel Non-Toxic Anticancer Drug with Methylglyoxal as the Lead Molecule
Dr. Manju Ray, Senior Professor & Head, Department of Biological Chemistry, Indian Association for the Cultivation of Science, Indian

16:30-16:50

Title: Sequential Small Molecular Dual Targeting Theragnostics: A Workable Strategy towards Improved Cancer Treatability or Curability?
Dr. Yicheng Ni, Professor, Catholic University Leuven, Belgium

16:50-17:10

Title: Leukemic Stem Cells: New Therapeutic Targets?
Dr. D Bonnet,Senior Group Leader, London Research Institute, Haematopoietic Stem Cell Laboratory, UK

Chair:

Dr. Jason K. Kim, Professor & Director, UMass Mouse Phenotyping Center, University of Massachusetts Medical School, USA

Dr. Jason Kim is a Professor of Molecular Medicine, Professor of Medicine in the Division of Endocrinology, Metabolism and Diabetes, and the Director of UMass Mouse Phenotyping Center at the University of Massachusetts Medical School.  He is an executive committee member of the Diabetes & Endocrinology Research Center, and an internationally recognized expert in mouse metabolism. Dr. Kim has performed diabetes research for more than 15 years, and his research is funded by the NIH, American Diabetes Association, and American Heart Association. He is an editorial board member for Diabetes, Endocrinology, and American Journal of Physiology and serves on multiple study sections including AHA and American Institute of Biological Sciences. He also serves as a consultant for leading pharmaceutical industries including Genzyme and Amgen and is a key scientific advisor for Escoublac. Dr. Kim has published more than 70 peer-reviewed articles, book chapters and reviews. Before joining UMass in 2008, he was an Associate Professor of Cellular & Molecular Physiology and the Director of Penn State Diabetes & Obesity Mouse Phenotyping Center at the Penn State College of Medicine from 2005 to 2008. 

Co-Chair:

Dr. Irina G. Obrosova, Director, Mechanisms of Diabetes Complications Laboratory, Pennington Biomedical Research Center, Louisiana State University, USA

13:30-13:50

Keynote Speech:
Title: Role of Inflammation in Diabetes
Dr. Jason K. Kim, Professor & Director, UMass Mouse Phenotyping Center, University of Massachusetts Medical School, USA

13:50-14:10

Title: Discovery and Characterization of Dapagliflozin, a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
Dr. William N Washburn, Senior Research Fellow, Bristol-Myers Squibb Pharmaceutical Research Institute, USA

14:10-14:30

Title : Thiazolidinediones Inhibit Aromatase Activity in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase and Altering the Enzyme Kinetic Properties
Dr. Donna Seto-Young, Director, Endocrinology & Metabolism Laboratory, Albert Eintein College of Medicine, USA

14:30-14:50

Title: Development of a Novel anti-Diabetes Agent
D r. Moon K. Song, Research Professor and Chief of Metabolic Disease Research, UCLA School of Medicine and VA Greater Los Angeles Healthcare System, USA

14:50-15:10

Title: PARP-1 as A Target for Treatment of Diabetic Complications
Dr. Ulrich Julius, Professor, Medical Clinic III, University Hospital Center, Germany

15:10-15:30

Coffee Break

15:30-15:50

Title: New Drug Targets for Treatment of DIabetic Neuropathy
Dr. Irina G. Obrosova, Director, Mechanisms of Diabetes Complications Laboratory, Pennington Biomedical Research Center, Louisiana State University, USA

15:50-16:10

Title: Design, Synthesis and Evaluation of Some Novel Glitazones for their Antihyperglycemic Activity
Dr. M. J. Nanjan, Professor & Director, JSS College of Pharmacy, India

16:10-16:30

Title: Exploiting the Antidiabetic and Anti Obesity Properties of Incretins and Their Analogues
Dr. L. Van Gaal, Professor, Dept. Endocrinology and Diabetology, Antwerp University Hospital, Belgium

16:30-16:50

Title: Suppression of Blood Glucose Elevation by L-tryptophan in Glucose-loaded Rats and Its Nobel Principal for Diabetes Therapy
Dr. Nobuhiko Katunuma, Professor, Tokushima Bunri University, Japan

16:50-17:10

Title: Design and Synthesis of Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type II Diabetes
Dr. Fanglong Yang, Director, Shanghai HengRui Pharmceutical Co.,Ltd. China

17:10-17:30

Chair:

Dr. Josy Breuer, Senior Director, Bayer Schering Pharma AG, Germany

Dr. Josy Breuer (MD, PhD) is a Senior Director, Global Clinical Development Diagnostic Imaging, at Bayer Schering Pharma AG. Since more than 10 years, Dr. Breuer leads clinical development programs for diagnostic imaging agents targeting several diseases and body regions, and directs Phase II and III clinical studies. The department covers conventional contrast agents development as well as molecular imaging agent, e.g. PET tracers. Before joining the pharmaceutical company, Dr. Breuer was specialized in Neurology and obtained the Medical Degree and the PhD from the Heinrich-Heine-University, Duesseldorf, Germany. During her resident time she was focusing on Neuroimaging and later on in neurodegenerative Diseases at the Central Institute for Mental Health, a WHO institute and branch of the University of Heidelberg, Germany.

Co-Chair:

Dr. Hans-Joachim Knolker, Professor, Organic Chemistry Department at the Technical University of Dresden (TUD), Germany

He studied chemistry at the Universities of Göttingen and Hannover (Germany), where he completed his PhD in 1985 on stereoselective annelation reactions. In his postdoctoral studies at the University of California at Berkeley in 1986, he investigated cobalt-mediated cycloadditions. After his return to the University of Hannover, he developed novel transition metal-mediated syntheses of biologically active heterocyclic compounds (1987–1990). He was full professor of organic chemistry at the University of Karlsruhe (1991–2001). Since 2001, he is full professor of organic chemistry at the Technical University of Dresden. He has been visiting professor in Japan and India and is cofounder of the biotech company JADO Technologies GmbH in Dresden. In 2006, he has been elected as an ordinary member of the Saxon Academy of Sciences. He is a fellow of the Japan Society for the Promotion of Science and of the Royal Society of Chemistry. His research interests include medicinal chemistry and the developent of novel methodologies for the synthesis of bioactive compounds (e.g., potential drugs against TB and Alzheimer’s disease).

Chair:

Dr. Johannes-Peter Stasch, Chief Scientist, Bayer HealthCare, Germany

Johannes-Peter Stasch is a Chief scientist in Cardiovascular Research at Bayer HealthCare in Wuppertal, and an Associate Professor of Pharmacology at the University Halle-Wittenberg, Germany . He earned his Ph.D. and Pharm.D. in Chemistry and Pharmaceutical Sciences from the University of Würzburg, Germany . He has more than 25 years' experience in the areas of molecular pharmacology, structure-based drug design and drug discovery in the CNS and cardiovascular fields, and in particular in neurotransmitters, natriuretic peptides, renin-angiotensin-aldosteron-system, adrenomedullin¸ adenosine, endothelin, and rho kinase. He has played a leading role in the discovery and development of the NO-independent sGC stimulators and sGC activators, and has published more than 100 peer-reviewed papers, multiple book chapters and filed more than 150 patent applications worldwide.

Co-Chair:

Dr. Gui-Rong Li, Associate Professor, Departments of Medicine and Physiology, Faculty of Medicine, The University of Hong Kong, Hongkong, China

Upon the completion of PhD in Pharmacology at Tongji Medical University in 1988, he was then trained in electrophysiology and electropharmacology in Dalhousie University and McGill University, Canada. He devotes most of his life to the study of ion channels, especially cardiac ion channels in different mammalian heart cells including human cardiac myocytes. His finding that the ultra-rapidly delayed rectifier potassium current (IKur) is present in atrial atria, but not in the ventricle of human heart (Li et al, 1996), leads to the strategy of developing selective IKur blocker for anti-atrial fibrillation. His group recently found that a compound from the traditional Chinese medicine selectively blocks atrial repolarization potassium currents, and shows a potential curable effect on atrial fibrillation (2008).

Chair:

Dr. Mitzi Nagarkatti, Chair, Dept. of Pathology, Microbiology and Immunology, University of South Carolina Cancer Center, USA

Dr. Nagarkatti is currently the Chair of the Dept. of Pathology, Microbiology and Immunology at the School of Medicine at the University of South Carolina, Columbia as well as Deputy Director for Basic Research at the University of South Carolina Cancer Center. The main research focus in Dr. Nagarkatti's laboratory is in the areas of Autoimmunity, Complementary and Alternative Medicine, Cancer Immunology and Immunotherapy and Biodefense. Dr. Nagarkatti's research has been continuously funded by agencies including the NIH, US Army, American Cancer Society (ACS), National Science Foundation/Environmental Protection Agency as well as other private foundations. Dr. Nagarkatti has recently been appointed to the National Toxicology Program (NTP) Board of Scientific Counselors. Dr. Nagarkatti has been the recipient of several awards such as the Pfizer Award for Research, Best Publication of the Year Award from the Society of Toxicology for her work on Immunotoxicology, the Shelton Horsley Research Award which is the highest award from the Virginia Academy of Sciences, and the Women in Science, Dentistry and Medicine Professional Development Award for outstanding accomplishments.

Co-Chair:

Dr. Shunlin Ren, Associate Professor, Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Virginia

Shunlin Ren, Biochemist and Associate Professor of Medicine, graduated in 1979 and got his M.S. degree from Department of Biochemistry, Shanghai First Medical College in 1985, and Ph.D. from Department of Biochemistry, Medical College of Virginia in 1992. He had postdoctoral training in Department of Pharmacology, Yale University School of Medicine in 1988-1989, and in Department of Biochemistry, Medical College of Virginia in 1992-1994. He was appointed as a faculty in 1994 and now serves as Associate Professor in the Department of Medicine, Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Richmond, Virginia . He received American Liver Scholar Award from American Association for Liver Study in 2002. His laboratories are focused on the cholesterol metabolism, nuclear orphan receptor activation/inactivation, characterization of nuclear oxysterols, the role of oxysterols in lipid metabolism and inflammatory response. His research is currently supported by NIH R01 and VA merit review grants.

Chair:

Dr. Bolin Geng, Principal Scientist, Infection Discovery, AstraZeneca R&D Boston, USA

Bolin Geng is a Principal Scientist of Infection Medicinal Chemistry Department at AstraZeneca R&D Boston, which he joined in 2002. Prior to that, Bolin was employed at Department of Medicinal Chemistry of ArQule as a Principal Investigator for six years. He is an inventor of several preclinical & clinical antibacterial drug candidates that are currently under development. Bolin obtained his PhD in organic chemistry from University of Montpellier, France and completed his post-doctoral training in medicinal chemistry at SMU. Earlier years, Bolin received his BS & MS education in organic chemistry from Nankai University, China. Bolin is a reviewer of following journals: Bioorganic & Medicinal Chemistry Letters; Journal of Combinatorial Chemistry; Analytical Biochemistry. He is an author / inventor of over thirty scientific publications and patents / patent applications in organic chemistry / discovery medicinal chemistry field. His most recent publications that related to the talk are: Bolin Geng, et al. Bioorg. Med. Chem. Lett. 2009, 19, 938-944; Bolin Geng, et al. Bioorg. Med. Chem. Lett. 2008, 18, 4368-4372.

Co-Chair:

Dr. Zuoyu Xu, Bacteriology Program Officer, Bacteriology and Mycology Branch, Division of Microbiology and Infectious Diseases, NIAID/NIH/HHS, USA

Zuoyu Xu, Ph.D., Program Officer, Bacteriology and Mycology, National Institute of Allergy and Infectious Diseases, NIH, the Department of Health and Human Services, USA(2007-present). Before being a US government official, Zuoyu was a Senior Principle Scientist at Pfizer Inc. (1998-2007) in Groton, Connecticut, leading projects on antibacterial drug discovery and development.  Dr. Xu graduated from Fudan University, Shanghai, received his B.S. in Microbiology (1982) and M.S. in Virology (1985), and joined the faculty of the Department of Biology, Fudan University in 1985. Zuoyu completed his Ph.D. with Dr. Robert Matts in Biochemistry and Molecular Biology at the Oklahoma State University in 1992, did postdoctoral research with Dr. Bill Wickner at University of California, Los Angeles and Dartmouth College. Zuoyu was an NIH fellow in Immunology in 1997 and earned certificate in Bioinformatics from Massachusetts Institute of Technology in 2001.

Chair:

Dr. Lieven Meerpoel, Head of Medicinal Chemistry Scientific Affairs, EDC, Johnson & Johnson Pharmaceutical Research and Development, Belgium

Lieven holds a Ph.D. (1992) in organic synthesis from the Catholique University Leuven under the supervision of prof. G. Hoornaert and did a post-doc (1993) with prof. P. Vogel in Lausanne, Switzerland . In 1993 he joined the Janssen Research Foundation, currently known as the Johnson & Johnson Pharmaceutical Research and Development. In 2001 he assumed responsibilities as head of the Synthesis Enabling Technology Group (SynTech). He was a key player in the implementation of Hit-to-Lead chemistry, and implemented multiple-step parallel solution phase and solid phase chemistry in hit and lead exploration. As a medicinal chemistry team leader he discovered 8 clinical candidates in the field of infectious and metabolic diseases and bactericidal compounds for protection of material deterioration. In 2003 he became head of Medicinal Chemistry Belgium and guided project chemistry team leaders in drug discovery. Since end of 2006 he installed and led a new group called Exploratory Research that is involved in drug repositioning and exploratory medicinal chemistry based on broad phenotypic and in vivo screening. In December 2007 he became RED EU, head of medicinal chemistry head andfrom January 2009 onwards head of medicinal chemistry scientific Affairs in EDC (European Discovery Capabilities). He is currently author and co-author of 50 publications and patents and founder and organizer of a series of J&J symposia on Drug Discovery. He is a board member of the Society of Combinatorial Sciences, Fellow of the faculty of Science from the KU Leuven, and member of the International Advisory Board of ChemMedChem, Wiley-VCH.

Co-Chair:

Dr. Derek Law, Head of Microbiology , F2G Ltd, UK

Chair:

Dr. Tao Wang, Principle Scientist, Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, USA

Dr. Wang received a B.S. in Organic Chemistry from Peking University in 1990 and a Ph.D. in Organic Chemistry under the supervision of Prof. Kang Zhao from New York University in 1996. After post-doctoral research with Prof. Gilbert Stork in Columbia University, Dr. Wang joined Anti-Viral Chemistry Department of Bristol-Myers Squibb R&D in 1998. Dr. Wang is the inventor of multiple first-in-class anti-HIV clinical molecules targeting gp120 of HIV, including BMS-378806 and BMS-488043. BMS-378806 was the first molecule reaching human clinical trials, and BMS-488043 was the” proof-of-concept” molecule which validated gp120 as a viable target for small molecule inhibitors. Dr. Wang is a co-inventor of 19 issued patents or patent applications, and a co-author of 32 published research articles, reviews and book chapters.

08:30-08:55

Keynote Speech:
Title: Development of HIV Entry Inhibitors Targeting the Gp41 Fusion Intermediate
Dr. Shibo Jiang, Professor, Lindsley F. Kimball Research Institute, New York Blood Center, USA

08:55-09:20

Title: HIV Attachment Inhibitors
Dr. Tao Wang, Principle Scientist, Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, USA

09:20-09:45

Title: Structural Features of Novel Native and Semi Synthetic Sulfated Polysaccharides with Potential as Antiretroviral Vaginal Microbicides
Dr. Shunchun Wang,Associate Research Fellow, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, China

09:45-10:05

Coffee Break

Chair:

Dr. Sandeep Mukherjee, Associate Professor, University of Nebraska Medical Center, USA

Sandeep Mukherjee graduated in medicine from the University of Wales College of Medicine in Cardiff, Wales and trained in Internal Medicine in the United Kingdom and United States. He completed a fellowship in Gastroenterology at the State University of New York Health Science Center in Syracuse, New York and a fellowship in Hepatology and Liver Transplantation at the University of Nebraska Medical Center in Omaha, Nebraska. He joined the University of Nebraska Medical Center and Omaha Veterans Affairs Medical Center in 2000 where he is currently Associate Professor of Internal Medicine. He was Chief of Gastroenterology and Hepatology at Omaha VAMC between 2005-2008. He is board-certified in Internal Medicine, Gastroenterology and Transplant Hepatology and has a Masters in Public Health from the Johns Hopkins Bloomberg School of Public Health. His clinical and research interests are in nonalcoholic fatty liver disease, viral hepatitis and endoscopy.

Co-Chair:

Dr. Xianfeng (Sam) Li, senior scientist, Anacor Pharmaceuticals, USA

Dr. Xianfeng Li joined Anacor as a senior scientist in 2007. Prior to that, he worked on medicinal chemistry projects for several biotech/pharmaceutical companies including Eli Lilly, Affymax Research Institute, Galileo Pharmaceuticals, and Genentech. He has a broad scope of experience in different therapeutic areas such as anti-infectives, anti-cancer, anti-inflammation, and anti-diabetes. Dr. Li received his BS from Huazhong Normal University, MS from University of Alberta, and PhD from University of Toronto. Dr. Li has authored or co-authored over 30 scientific publications and patents.

10:05-10:30

Keynote Speech:
Title: Discovery of Novel and Highly Active Phosphonate Derivatives as Hepatitis C Virus NS3 Protease Inhibitors.
Dr. Xiaoning C. Sheng, Director, Gilead Sciences, Inc., USA

10:30-10:55

Title: Treatment of Recurrent Hepatitis C After Liver Transplantation
Dr. Sandeep Mukherjee, Associate Professor, University of Nebraska Medical Center, USA

10:55-11:20

Title: Novel Cyclic Boronates as HCV NS3/4A Protease Inhibitors
Dr. Xianfeng (Sam) Li, Senior Scientist, Anacor Pharmaceuticals, USA

11:20-11:45

Title: Monoclonal Antibodies Targeting the E1E2 Envelope Complex of Serum-Derived Hepatitis C Virus Particles–New Potential Diagnostic and Immuntherapeutic Applications
Dr. Marie-Anne Petit, Research Director,INSERM Unit 871, France

11:45-12:10

Title: ISG15, an Ubiquitin-like Interferon Stimulated Gene, Promotes HCV Production in Vitro
Dr. Limin Chen, Research Associate , University of Toronto, Canada

Chair:

Dr. Christoph Moroni, Professor, University of Basel, Switzerland

Christoph Moroni, M.D., Professor of Medical Microbiology, is currently at the Biozentrum, University of Basel, Switzerland . After postdoctoral training at the Salk Institute ( La Jolla, USA ) he was a group leader at the Friedrich Miescher Institute in Basel, and was appointed 1987 professor and director of the Institute for Medical Microbiology at the University of Basel . He was also Chairman for the Department of Clinical and Biological Sciences (2000-2006) and was member of the Research Council of the Swiss National Foundation for Research. He served on several national and international boards. His research concentrated on tumor virology, molecular biology and experimental oncology.

Co-Chair:

Dr. Prakash Nagarkatti, Associate Dean, University of South Carolina, Columbia, USA

Dr. Prakash Nagarkatti is currently the Associate Dean at the University of South Carolina School (USC) of Medicine. He also serves as an Advisor to the Vice President for Research at USC and as Carolina Distinguished Professor. He received his Ph.D. at Defense Research and Development Establishment, India in 1980 and pursued post-doctoral research at the McMaster University, Canada and the University of Kentucky, USA. He held faculty and endowed Chair positions at Virginia Tech and at the Medical College of Virginia before joining USC. Dr. Nagarkatti has worked primarily in the areas of immune response as it relates to cancer and autoimmune diseases. Currently, he also serves as a Principal Investigator and Director of a newly funded $6 million Center by the National Institutes of Health (NIH) at USC where he and his collaborators are working on compounds such as resveratrol and cannabinoids for their anti-inflammatory properties and regulation of Th17 vs Tregs. Dr. Nagarkatti’s lab has worked extensively on targeting cytokines and chemokines in the treatment of cancer and autoimmunity.

08:30-08:50

Keynote Speech:
Title: Cannabinoids as a new class of anti-cancer drugs
Dr. Prakash Nagarkatti, Associate Dean, University of South Carolina, Columbia, USA

08:50-09:10

Title: Insulin-like Growth Factor Receptor as a Target of Anti-Cancer Drugs
Dr. Valentina Tzekova, Professor, University Hospital "Queen Joanna-ISUL", Bulgaria

09:10-09:30

Title: Natural Phytochemicals as Small Molecular Inhibitors of Signal Transduction Molecules for Cancer-Prevention
Dr. Ki Won Lee, Assistant Professor, Department of Bioscience and Biotechnology, Konkuk University, Korea

09:30-09:50

Title: Discovery Of Triazole Nucleosides With Potent Anticancer
Activity Against Drug-Resistant Pancreatic Cancer
Dr. Yi Xia, College of Chemistry and Molecular Sciences, Wuhan University, China

09:50-10:10

Title: A Genome-scale shRNA Screen to Identify Genes Encoding Potential Drug Targets
Dr. Christoph Moroni, Professor, University of Basel, Switzerland

10:10-10:30

Coffee Break

10:30-10:50

Title: Nanotechnology in Cancer
Dr. Manfred George Krukemeyer, Professor, Department of Radio-Oncology, Paracelsus Hospital Osnabrück, Germany

10:50-11:10

Title: Topological Polar Surface Area Defines Substrate Transport by Multidrug Resistance Associated Protein 1 (MRP1/ABCC1)
Dr. Janaina Fernandes, Professor, Universidade Federal do Rio de Janeiro, Brazil

11:10-11:30

Title: Regulation of p21, MMP-1 and MDR-1 expression in Human colon carcinoma HT29 by Tian Xian Liquid, a Chinese Medicine Formula, in vitro and in vivo
Dr. Tong Yao, Professor, University of Hong Kong, China

11:30-11:50

Title: The Use of Sea Urchin Embryo Model for the Development of New Antimitotic Molecules
Dr. Marina Semenova, Senior Research Scientist, Institute of Developmental Biology, Russian Academy of Sciences, Russia

11:50-12:10

Title: Dihydroartemisinin Improves the Efficiency of Chemotherapeutics in Lung Carcinomas in Vivo and Inhibits Murine Lewis Lung Carcinoma Cell Line Growth in Vitro
Dr. Huijun Zhou, Associate Researcher, Zhejiang University, China

Chair:

Dr. Andrew C. Chang, Executive Director, Pharmanet Development Group, Inc., USA

Dr. Chang has more than 17 years of experience with biologics and pharmaceuticals. Prior to joining PharmaNet in 2006, he served more than 11 years at US FDA, most recently as an Associate Director for Policy and Regulation and Senior Regulatory Scientist in the Division of Hematology, Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER). He is known nationally and internationally for his significant scientific and regulatory contributions to the development, approval and post market surveillance of recombinant and naturally-derived products used in therapy. He had served as the review committee chairperson for the licensures of four new and novel recombinant and naturally-derived products, and for the approval of hundreds post-marketing supplements. In 2002, FDA recognized Dr. Chang as the FDA regulatory expert in the regulation of new and novel recombinant products as well as naturally-derived biological products. While at FDA, Dr. Chang was known as a leading FDA and CBER spokesperson and has presented the FDA perspective at many national and international meetings. Dr. Chang also served as the FDA deputy topic leader for ICH Q5E guideline and the FDA observer for European and US Pharmacopeia’s Expert Groups on Blood and Blood Derived Products.

Co-Chair:

Dr. Liang Tang, Principal Research Scientist, Bayer HealthCare, USA

Dr. Liang Tang has more than 20 years of experience in protein biochemistry, molecular biology and immunology. He has over 14 years of pharmaceutical industry experience in drug discovery research. He has extensive experiences in protein expressions using different cell systems (especially mammalian cell system), protein purification/ modification and in vitro/in animal characterizations. He is currently a principle research scientist in the Bayer Protein Therapeutic Division involving in the discovery of new protein therapeutic molecules for different indications.

13:30-13:55

Keynote Speech:
Title: Biotherapeutics in 21st Century: What Challenges and Opportunities Can We Expect?
Dr. Sandeep Nema,Executive Director, Pfizer Global Biologics, St. Louis Laboratory, USA

13:55-14:20

Title: RNAi and Knockout Technology Application in Protein Engineering to Improve the Therapeutic Protein Efficacy
Dr. Amy Shen, Senior Manager/Group Leader, Early Stage Cell Culture, Genentech, Inc.,US

14:20-14:45

Title: The Engineered Serine Protease Inhibitor MDPK67b for the Treatment of Diseases Involving Hyperactivity of Human Kallikreins
Dr. David Deperthes, CEO and President, Med Discovery SA, Switzerland

14:45-15:10

Title: Factors for Consideration in Assessing Comparability of Follow-on Protein Products
Dr. Andrew C. Chang,Executive Director, Pharmanet Development Group, Inc., USA

15:10-15:30

Coffee Break

15:30-15:55

Title: Protein Drug Delivery and Challenges
Dr. Ning Li, Senior Principal Scientist, Pfizer Global Biologics, St. Louis Laboratory, USA

15:55-16:20

Title: Modification of Protein Therapeutic for Enhancing its Therapeutic Properties in vivo
Dr. Liang Tang, Principal Research Scientist, Bayer HealthCare, USA

16:20-16:45

Title: Development of Protein Agent for Diabetes Treatment by Rationale Design
Dr. Zhi-Ren Liu, Associate Professor, Georgia State University, USA

16:45-17:10

Title: Molecular Display and Protein Drug Discovery
Dr. Lin Sun, Research Project Leader, Massachusetts General Hospital, USA

17:10-17:30

Panel Discussion
3-5 Topics will be Proposed by Session Chair

Chair:

Dr. Mitchell Ho, Head, Antibody Therapy Unit, National Cancer Institute, NIH, USA

Dr. Mitchell Ho is an Investigator and Head of the Antibody Therapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, National Institutes of Health. Research in Dr. Ho’s laboratory is aimed at understanding the molecular mechanisms underlying cancer and developing novel anti-cancer antibody therapies. Current efforts focus on building new therapeutic antibodies directed at ovarian cancer, mesothelioma and liver cancer. Dr. Ho received his Ph.D. in Immunology from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NIH working on immunotoxin therapy of cancer. Dr. Ho is a recipient of Mesothelioma Applied Research Foundation Award, and Ovarian Cancer Research Fund Individual Investigator Award.

Co-Chair:

Dr. Duu-Gong Wu, Executive Director, Consulting Division, PharmaNet, Inc., USA

Dr. Wu is currently Executive Director of Pharmanet Consulting Division.   Prior to joining PharmaNet in March 2004, he had worked at FDA Center for Drug Evaluation and Research (CDER) for 12 plus years with the last position serving as Deputy Division Director, Division of New Drug Chemistry II.  His career at FDA encompassed a unique combination of extensive regulatory experience in both biotechnological/biological products and drugs of small molecules. In addition to a large number of IND/NDA reviews, his experience in biotechnological drug products also includes a member of ICH Expert Working Groups for both Q5E (Comparability of Biotechnology) and CTD-Q (Common Technical Document-Quality).  He also served as Chairman of CDER Protein Drug Products Technical Committee, Chairman of follow-on growth hormone and insulin Working Group, which drafted a unpublished guidance and policies related to Omnitrope’s review and approval.  He also served a member of FDA Follow-on Biologic Working Group, and Ad Hoc Reviewer associated with USP Biotechnology Committee. Previously, he also participated in the drafts of ICH Q6B and Q5C for biotechnological drug products and numerous CDER/CBER guidances/guideline related to CMC issues of biological products.

08:30-08:50

Keynote Speech:
Title: Therapeutic Antibodies and Beyond: Current State and Future Trends
Dr. Dimiter S Dimitrov, Head, Protein Interaction Group, Senior Investigator, National Cancer Institute, NIH, USA

08:50-09:10

Title: Clinical Development of the Trifunctional, Bispecific Anti-EpCAM Antibody Catumaxomab
Dr. Rolf Linke, Vice President,Clinical Development and Medical Affairs, Fresenius Biotech GmbH, Germany

09:10-09:30

Title: Targeting Mesothelin in Ovarian Cancer and Mesothelioma
Dr. Mitchell Ho, Head, Antibody Therapy Unit, National Cancer Institute, NIH, USA

09:30-09:50

Title: Selection of High-value Cell Lines for Monoclonal Antibody Expression Using ClonePix FL.
Dr. Gabe Longoria, Director, Genetix Ltd., UK

09:50-10:10

Title: Design and Engineering of Multi-specific Antibodies
Dr. Changshou Gao, Principal Scientist, MedImmune, LLc., USA